Chronic Lymphocytic Leukemia

Author
Sol Atienza Yoder, Pharm.D., BCOP
Oncology Pharmacy Clinical Coordinator
Resident Program Director
Department of Pharmacy Services
Aurora Health Care
Milwaukee, Wisconsin

Reviewers
Kristen McCullough, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist-Hematology/Oncology
Department of Pharmacy Services
Mayo Clinic
Rochester, Minnesota

Mary Samy Kelada, Pharm.D., BCPS, BCACP
Pharmacist
Pharmacy Department
University Hospital, Parma Medical Center
Parma, Ohio

Donald C. Moore III, Pharm.D., BCPS, BCOP
Pharmacist Clinical Coordinator-Oncology
Department of Pharmacy
Levine Cancer Institute
Charlotte, North Carolina

Multiple Myeloma

Author
Houry Leblebjian, Pharm.D., BCOP
Hematology/Oncology Clinical Pharmacy Specialist
Pharmacy Department
Dana Farber Cancer Institute
Boston, Massachusetts

Reviewers
Monique Giordana, Pharm.D., BCOP
Hematology/Oncology Clinical Pharmacy Specialist
Department of Pharmacy
Regions Hospital
Saint Paul, Minnesota

Joanna Ferraro, Pharm.D., BCACP
Bemidji, Minnesota

Kathryn A. Wheeler, Pharm.D., BCPS, BCOP
Clinical Pharmacist, Oncology
SSM Cancer Care
SSM Health/DePaul Health
St. Peters, Missouri

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Hematologic Care I chapters:

Emilie L. Karpik, Pharm.D., BCPS
Oncology Pharmacist
Department of Pharmacy
Froedtert Hospital
Milwaukee, Wisconsin

Ralph H. Raasch, Pharm.D., FCCP, BCPS
Associate Professor of Pharmacy (retired)
Division of Practice Advancement and Clinical Education
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Alexandre Chan (Merck Sharp & Dohme, Mundipharma); Lisa M. Holle (HOPA, Innovrin Pharmaceuticals); Robert Mancini (Taiho Pharmaceuticals); Kristen McCullough (HOPA); Cindy L. O’Bryant (Heron Therapeutics); Kamakshi V. Rao (BPS Oncology Specialty Council); Vivian Tsang (HOPA); Sol Atienza Yoder (HOPA, BPS Oncology Specialty Council)

Stock Ownership: Stephanie Gaston (Fred Meyer)

Royalties: Karen L. Kier (McGraw-Hill Medical Publishing)

Grants: Cindy L. O’Bryant (Astra Zeneca); Kamakshi V. Rao: Grants (University Cancer Research Fund, HOPA Foundation, UNC Gillings School of Global Public Health)

Honoraria: Grace M. Akoh-Arrey (Sanofi Aventis); Alexandre Chan (Merck Sharp & Dohme); Lisa M. Holle (Connecticut Pharmacists Association); Kristen McCullough (Medscape/Web MD); Cindy L. O’Bryant (Amgen); Bobbie Williamson (Northwest AHEC)

Other:

Nothing to disclose: Shimaa Elsayed Ahmed; Shubha Bhat; Sara K. Butler; Lisa M. Cordes; Diane M. Erdman; Joanna Ferraro; Kimberly N. Flynn; Monique Giordana; Mary Samy Kelada; Houry Leblebjian; Joyce Y. Lee; Stephanie Su Wen Lim; Tristan Lindfelt; Lisa K. Lohr; Donald C. Moore III; Rita Morelli; Michelle Musser; LeAnn B. Norris; Lisa M. Thompson; Kellie Jones Weddle; Kathryn A. Wheeler; Eva Y. Wong; Chrystia M. Zobniw

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. ACSAP has been approved by BPS for use in BCACP recertification. Information about the BPS recertification process is available online.

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties
2215 Constitution Avenue NW
Washington, DC 20037
(202) 429-7591